CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry
Part of paid clinical trials in Waltham, Massachusetts.
- Sponsor
- CorEvitas
- Study ID
- NCT05745389
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
Prospective, observational cohort study for subjects with AA under the care of a dermatology provider. Approximately 5,000 subjects and 100 clinical sites in North America will be recruited to participate with no defined upper limit for either target.
Key Dates
- Start date
- Oct 25, 2022
- Status verified
- Jan 2026
- Primary completion
- Dec 31, 2099
- Completion
- Dec 31, 2099
Study Design
- Enrollment
- 5,000 participants (estimated)
Arms
- Arm: Alopecia AreataPts presenting to enrolling sites across the US are invited to enroll if eligible
Primary Outcome Measure
Alopecia epidemiology, presentation, natural history, management, and outcomes [ Time Frame: A minimum of 10 years from last patient enrolled ]
Central Contacts
- Cathy Cheney(508) 408-5435
- Resham Sanzagiri508-948-0898
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| CorEvitas, LLC | Waltham | Massachusetts | 02451 | Jeffrey Greenberg |
Find similar trials in Waltham, MA
By research site
Related Studies
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia AreataPHASE3 · Recruiting · AbbVie · Birmingham, Alabama
- Characterization And Clinical Outcomes of AA Patients Treated With RitlecitinibRecruiting · Pfizer · Montgomery, Alabama
- CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness RegistryRecruiting · CorEvitas · Waltham, Massachusetts
- A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)PHASE2 · Recruiting · Eli Lilly and Company · Fremont, California